Gataparsen

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGataparsen
Drug Alias NameLY-2181308ISIS-23722
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionBaculoviral IAP repeat-containing protein 5 inhibitorsProtein biosynthesis inhibitors
TargetsBaculoviral IAP repeat-containing protein 5
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG